Prothena to Report Third Quarter 2024 Financial Results on November 12
Prothena (NASDAQ:PRTA) announced it will release its third quarter and first nine months of 2024 financial results on Tuesday, November 12, 2024, after U.S. financial markets close. The company, a late-stage clinical biotechnology firm focusing on protein dysregulation expertise, stated it will not hold a conference call following the financial results release, which is consistent with their previous practices.
Prothena (NASDAQ:PRTA) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre e dei primi nove mesi del 2024 martedì 12 novembre 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda, una società biotecnologica clinica in fase avanzata che si concentra sull'esperienza nella disregolazione delle proteine, ha dichiarato che non terrà una conferenza telefonica dopo la pubblicazione dei risultati finanziari, in linea con le loro pratiche precedenti.
Prothena (NASDAQ:PRTA) anunció que publicará sus resultados financieros del tercer trimestre y de los primeros nueve meses de 2024 el martes 12 de noviembre de 2024, después del cierre de los mercados financieros en EE. UU. La compañía, una empresa de biotecnología clínica en etapa avanzada que se centra en la experiencia en disfunción de proteínas, declaró que no realizará una llamada de conferencia tras la publicación de los resultados financieros, lo cual es consistente con sus prácticas anteriores.
프로세나 (NASDAQ:PRTA)는 2024년 3분기 및 처음 9개월의 재무 결과를 2024년 11월 12일 화요일, 미국 금융 시장이 종료된 이후에 발표할 것이라고 발표했습니다. 이 회사는 단백질 조절 해석에 중점을 둔 후기 단계 임상 생명공학 회사로, 재무 결과 발표 후 컨퍼런스 콜을 진행하지 않을 것이라고 밝혔으며, 이는 이전 관행과 일치합니다.
Prothena (NASDAQ:PRTA) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre et des neuf premiers mois de 2024 le mardi 12 novembre 2024, après la fermeture des marchés financiers américains. L'entreprise, une société de biotechnologie clinique en phase avancée spécialisée dans l'expertise en dysrégulation des protéines, a déclaré qu'elle ne tiendrait pas de conférence téléphonique après la publication des résultats financiers, ce qui est conforme à ses pratiques antérieures.
Prothena (NASDAQ:PRTA) gab bekannt, dass die finanziellen Ergebnisse für das dritte Quartal und die ersten neun Monate des Jahres 2024 am Dienstag, dem 12. November 2024, nach dem Schluss der US-Finanzmärkte veröffentlicht werden. Das Unternehmen, eine biopharmazeutische Firma in der späten klinischen Phase, die sich auf die Expertise in Bezug auf Protein-Dysregulation konzentriert, erklärte, dass nach der Veröffentlichung der finanziellen Ergebnisse kein Konferenzanruf stattfinden wird, was im Einklang mit ihren früheren Praktiken steht.
- None.
- None.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 12.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105448529/en/
Investors
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Source: Prothena Corporation plc
FAQ
When will Prothena (PRTA) release Q3 2024 financial results?
Will Prothena (PRTA) hold a conference call for Q3 2024 earnings?
What period will Prothena's (PRTA) upcoming financial report cover?
